These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 38004151)

  • 1. The Role of Epigenetic Control of Mitochondrial (Dys)Function in MASLD Onset and Progression.
    Caputo V; Tarantino G; Santini SJ; Fracassi G; Balsano C
    Nutrients; 2023 Nov; 15(22):. PubMed ID: 38004151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thyroid Hormone and Mitochondrial Dysfunction: Therapeutic Implications for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    Ramanathan R; Patwa SA; Ali AH; Ibdah JA
    Cells; 2023 Dec; 12(24):. PubMed ID: 38132126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitochondrial Quality Control: Its Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
    Shin S; Kim J; Lee JY; Kim J; Oh CM
    J Obes Metab Syndr; 2023 Dec; 32(4):289-302. PubMed ID: 38049180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetics and mitochondrial dysfunction insights into the impact of the progression of non-alcoholic fatty liver disease.
    Guha S; Sesili S; Mir IH; Thirunavukkarasu C
    Cell Biochem Funct; 2023 Jan; 41(1):4-19. PubMed ID: 36330539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological therapy of metabolic dysfunction-associated steatotic liver disease-driven hepatocellular carcinoma.
    Wang Y; Fleishman JS; Li T; Li Y; Ren Z; Chen J; Ding M
    Front Pharmacol; 2023; 14():1336216. PubMed ID: 38313077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A crosstalk between epigenetic modulations and non-alcoholic fatty liver disease progression.
    Ramezani M; Zobeiry M; Abdolahi S; Hatami B; Zali MR; Baghaei K
    Pathol Res Pract; 2023 Nov; 251():154809. PubMed ID: 37797383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physical exercise and liver "fitness": Role of mitochondrial function and epigenetics-related mechanisms in non-alcoholic fatty liver disease.
    Stevanović J; Beleza J; Coxito P; Ascensão A; Magalhães J
    Mol Metab; 2020 Feb; 32():1-14. PubMed ID: 32029220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting Mitochondria for the Prevention and Treatment of Nonalcoholic Fatty Liver Disease: Polyphenols as a Non-pharmacological Approach.
    Zapata J; Castro-Sepulveda M; Soto-Alarcon S; Alvarez D; Bustamante A; Villarroel G; Gallardo A; Garcia-Diaz DF; Valenzuela R; Echeverria F
    Curr Med Chem; 2023; 30(26):2977-2995. PubMed ID: 36214303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential epigenetic mechanism in non-alcoholic Fatty liver disease.
    Sun C; Fan JG; Qiao L
    Int J Mol Sci; 2015 Mar; 16(3):5161-79. PubMed ID: 25751727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Steatotic Liver Disease: Metabolic Dysfunction, Alcohol, or Both?
    Staufer K; Stauber RE
    Biomedicines; 2023 Jul; 11(8):. PubMed ID: 37626604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitochondrial GpC and CpG DNA Hypermethylation Cause Metabolic Stress-Induced Mitophagy and Cholestophagy.
    Theys C; Ibrahim J; Mateiu L; Mposhi A; García-Pupo L; De Pooter T; De Rijk P; Strazisar M; İnce İA; Vintea I; Rots MG; Vanden Berghe W
    Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetics in non-alcoholic fatty liver disease.
    Lee J; Kim Y; Friso S; Choi SW
    Mol Aspects Med; 2017 Apr; 54():78-88. PubMed ID: 27889327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitochondrial dysfunction and epigenetics underlying the link between early-life nutrition and non-alcoholic fatty liver disease.
    La Colla A; Cámara CA; Campisano S; Chisari AN
    Nutr Res Rev; 2023 Dec; 36(2):281-294. PubMed ID: 35067233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of CYP2E1 in Mitochondrial Dysfunction and Hepatic Injury by Alcohol and Non-Alcoholic Substances.
    Abdelmegeed MA; Ha SK; Choi Y; Akbar M; Song BJ
    Curr Mol Pharmacol; 2017; 10(3):207-225. PubMed ID: 26278393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mitochondrial dysfunction in high-fat diet-induced nonalcoholic fatty liver disease: The alleviating effect and its mechanism of Polygonatum kingianum.
    Yang XX; Wang X; Shi TT; Dong JC; Li FJ; Zeng LX; Yang M; Gu W; Li JP; Yu J
    Biomed Pharmacother; 2019 Sep; 117():109083. PubMed ID: 31387169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antioxidant Versus Pro-Apoptotic Effects of Mushroom-Enriched Diets on Mitochondria in Liver Disease.
    Fontes A; Alemany-Pagès M; Oliveira PJ; Ramalho-Santos J; Zischka H; Azul AM
    Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31426291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Interplay between Endocrine-Disrupting Chemicals and the Epigenome towards Metabolic Dysfunction-Associated Steatotic Liver Disease: A Comprehensive Review.
    Mentsiou Nikolaou E; Kalafati IP; Dedoussis GV
    Nutrients; 2024 Apr; 16(8):. PubMed ID: 38674815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interplay between early-life malnutrition, epigenetic modulation of the immune function and liver diseases.
    Campisano S; La Colla A; Echarte SM; Chisari AN
    Nutr Res Rev; 2019 Jun; 32(1):128-145. PubMed ID: 30707092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring the landscape of steatotic liver disease in the general US population.
    Ciardullo S; Carbone M; Invernizzi P; Perseghin G
    Liver Int; 2023 Nov; 43(11):2425-2433. PubMed ID: 37592856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic and epigenetic variants influencing the development of nonalcoholic fatty liver disease.
    Li YY
    World J Gastroenterol; 2012 Dec; 18(45):6546-51. PubMed ID: 23236228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.